Clinical trials: Decompensated Liver Cirrhosis
Decompensated Cirrhosis
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1)
This is a Phase 1, open label, dose escalation clinical trial of human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis.
- Trial name
- NCT05227846
- Testing
- Human Umbilical Cord-derived Mesenchymal Stem Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing 302 Hospital
Liver Cirrhosis, Alcoholic
Feasibility of Wearable Biosensors for Monitoring Daily Activity, Heart Rate, and Sleep Among Patients With Decompensated Cirrhosis
In this protocol, the investigators will determine compliance, acceptability, and patient satisfaction regarding the use of remote monitors and summarize changes in activity over time among patients with decompensated cirrhosis.
- Trial name
- NCT06057870
- Testing
- Application on Apple watch
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Cirrhoses, Liver
Simvastatin Plus Rifaximin in Decompensated Cirrhosis
The main purpose of this study is to investigate whether the combination of two different drugs, simvastatin and rifaximin, is safe in the treatment of patients with decompensated cirrhosis.
- Trial name
- LIVERHOPE (NCT03150459)
- Testing
- Simvastatin 20 mg, Simvastatin 40mg, Rifaximin 400 mg
- Where
- 9 sites in France, Germany and 4 more
- Volunteers
- 44 people
- Sponsor
- Judit Pich
Decompensated Cirrhosis, Portal Hypertension
The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS
The aim of this study is to evaluate the effectiveness of L-ornithine-L-aspartate (LOLA) on plasma ammonia in cirrhotic patients after Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure.
- Conditions
- Decompensated Cirrhosis, Portal Hypertension, Bleeding Varices, Refractory Ascites
- Trial name
- NCT01440829
- Testing
- L-ornithine-L-aspartate
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Air Force Military Medical University, China
Cirrhosis, Liver, Rectal Colonization
Longitudinal Surveillance of Rectal Colonization and Transmission by Resistant Bacteria in Acutely Decompensated Cirrhosis
Antimicrobial resistance has emerged as a global threat, and multidrug resistance organisms (MDROs) form one of the foremost challenges in the setting of decompensated cirrhosis.
- Conditions
- Cirrhosis, Liver, Rectal Colonization, Multidrug Resistance Organisms
- Trial name
- NCT06511492
- Testing
- No intervention in this study
- Volunteers
- 1,289 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis B, Cirrhosis
A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.
This trial is being done to see if the investigational drug, LdT (Telbivudine), is safe and effective in the treatment of hepatitis B infection.
- Trial name
- NCT00275652
- Testing
- LdT (Telbivudine) and lamivudine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Cirrhosis, Alcohol Related Liver Disease
Clinical Characteristics of Recompensation
Recompensation in decompensated liver cirrhosis is an emerging clinical endpoint; however, standardized criteria and long-term prognostic data are currently lacking.
- Conditions
- Cirrhosis, Alcohol Related Liver Disease, HBV (Hepatitis B Virus), Recompensation
- Trial name
- NCT07651683
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Acute Liver Failure, Liver Cirrhosis
Indocyangreen Elimination in Cirrhosis and Acute Liver Failure
Indocyangreen (ICG)is totally biliary eliminated and corresponds to hepatocyte function and liver perfusion. The ICG-clearance will be evaluated as a prognostic marker in liver disease.
- Trial name
- NCT00245310
- Testing
- Indocyangreen (ICG) clearance
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Heidelberg University
Decompensated Cirrhosis
A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis
This study protocol is designed to evaluate the clinical efficacy, safety, and tolerability of HCL001 cell injection in the treatment of decompensated cirrhosis.
- Trial name
- NCT06306781
- Testing
- HCL001 cell (homologous allogeneic hepatocytes) injection
- Volunteers
- 18 people
- Sponsor
- RenJi Hospital
Liver Cirrhosis
PiCCO Guided Therapy in Liver Cirrhosis
Prospective comparison of standard therapy in liver cirrhosis versus standard therapy plus intensified hemodynamic monitoring using the PiCCO system.
- Trial name
- NCT00232427
- Testing
- Hemodynamic monitoring system PiCCO
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Heidelberg University
Liver Cirrhosis
Trial of Mesenchymal Stem Cell Transplantation in Decompensated Liver Cirrhosis
There has been great interest in recent years to take advantage of stem cells to treat liver cirrhosis. Mesenchymal stem cells (MSC) has been shown to be safe and effective for liver diseases in some studies.
- Trial name
- NCT03209986
- Testing
- mesenchymal stem cell transplantation via peripheral vein, mesenchymal stem cell
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Cirrhosis, Liver
Microbiome Translocation in Different Circulatory Compartments in Decompensated Cirrhosis
Acquired dysfunctional immunity in cirrhosis predisposes patients to frequent bacterial infections contributing to disease progression and may lead to the development of acute-on-chronic liver failure (ACLF).
- Trial name
- NCT04195724
- Testing
- mNGS for pathogen detection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Decompensated Cirrhosis
Efficacy of High Dose Albumin Therapy in Improving Liver Transplant-free Survival in Patients With Acute Decompensation of Cirrhosis
Research Objectives- We hypothesized high-dose 25% albumin would be superior to standard medical treatment in improving 3-month mortality in patients with acute decompensation of cirrhosis by improving the systemic hemodynamics…
- Trial name
- NCT05956197
- Testing
- No intervention
- Where
- India
- Volunteers
- 55 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis
Mesenchymal Stem Cell Transplantation in Decompensated Cirrhosis
The standard treatment for decompensated cirrhosis is liver transplantation, however, it has several limitations. Recent animal studies suggest that bone marrow stem cell transplantation can lead to regression of liver fibrosis.
- Trial name
- NCT00476060
- Testing
- Autologous mesenchymal stem cell transplantation
- Where
- Iran
- Volunteers
- 27 people
- Sponsor
- University of Tehran